Moderna Gets Clearance to Start Phase 2 Trial on CCP Virus Vaccine

A pharmacist gives Jennifer Haller the first shot in the first-stage safety study clinical trial of a potential vaccine for the CCP virus, at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16, 2020. The vaccine was developed by Moderna. Ted S. Warren/AP Photo

Drugmaker Moderna has obtained clearance from the Food and Drug Administration to run a larger trial of its CCP virus vaccine candidate.

The state of the phase two trial is “imminent,” Moderna CEO Stéphane Bancel said in a statement. The trial will include 600 participants.